Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / gigagen partners with the national cancer institute mwn benzinga


GRFS - GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564 | Benzinga

  • Collaboration sets stage for GigaGen's first oncology asset to enter clinical development

    GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade

    GigaGen and NCI will present investigational new drug (IND)-enabling data and clinical trial strategy for GIGA-564 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --   GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed an agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to advance development of the company's differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564.

    This Cooperative Research and Development Agreement enables further preclinical and clinical studies to assess GIGA-564's potential across various tumor types, including the first in-human Phase 1 clinical trial for the drug candidate in advanced solid tumors.

    "We are proud to receive the NCI's support and partner with their esteemed clinical research team to drive the GIGA-564 program forward," said Carter Keller, senior vice president of Grifols and head of GigaGen. "GIGA-564 represents a new approach to designing anti-CTLA-4 agents with potential not only to enhance anti-tumor activity but also to mitigate immune-related toxicities typically associated with first generation anti-CTLA-4 therapies. We look forward to continuing to demonstrate its potential in a clinical setting as we plan to file the IND application for our first Phase 1 clinical trial in advanced solid tumors before the end of 2023."

    This agreement signifies a milestone for GigaGen, as GIGA-564 could be the company's first oncology candidate to reach clinical stage.

    GIGA-564, a fully human monoclonal antibody, distinguishes itself from currently available anti-CTLA-4 drugs. Previous anti-CTLA-4 drugs were designed to strongly block CTLA-4's interaction with its ligands, thereby enhancing T cell co-stimulation. However, this approach has been associated with heightened immune-related side effects.

    Moreover, recent insights reveal that previous anti-CTLA-4 drugs contribute to an increased proliferation of T regulatory cells (Tregs), which may dampen their intended effect of activating cytotoxic T cells that are vital for attacking tumors. In comparison, GIGA-564's uniqueness stems from its minimal CTLA-4 blockade and its ability to deplete intratumoral Tregs within the tumor microenvironment. This distinctive mode of action has translated into superior anti-tumor performance and reduced immune-related toxicity in ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Grifols S.A.
    Stock Symbol: GRFS
    Market: NASDAQ
    Website: grifols.com

    Menu

    GRFS GRFS Quote GRFS Short GRFS News GRFS Articles GRFS Message Board
    Get GRFS Alerts

    News, Short Squeeze, Breakout and More Instantly...